Bristol Myers Squibb: A Pharma Giant Trading Like Growth Is Over – It’s Not
Bristol Myers Squibb: A Pharma Giant Trading Like Growth Is Over – It’s Not The market narrative around Bristol Myers Squibb (BMY) has turned decidedly gloomy. With patent cliffs looming and generic competition rising, investors have treated the stock as if its growth story is finished. The Market’s Myopic View on Big Pharma Wall Street…